---
title: "European stocks \"Eleven Arhats\" | Novo Nordisk fell about 8.1%, ASML dropped over 4%"
description: "On Monday (March 10), European stocks performed poorly, with Novo Nordisk down 8.07% and ASML Holdings down 4.05%. Novo Nordisk's stock price closed at 549.40 Danish kroner, falling below the 600 mark"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/231254181.md"
published_at: "2025-03-10T17:01:09.000Z"
---

# European stocks "Eleven Arhats" | Novo Nordisk fell about 8.1%, ASML dropped over 4%

> On Monday (March 10), European stocks performed poorly, with Novo Nordisk down 8.07% and ASML Holdings down 4.05%. Novo Nordisk's stock price closed at 549.40 Danish kroner, falling below the 600 mark for the first time. SAP SE dropped 4.78%, and AstraZeneca fell 1.91%. In contrast, companies like Roche, Novartis, and Nestlé saw slight increases in their stock prices, with L'Oréal up 1.38% and GlaxoSmithKline up 1.6%

On Monday (March 10), ASML Holding's stock price in Amsterdam (ASML.NA) closed down 4.05% at €639.00. Novo Nordisk's stock price in Copenhagen (NOVOB.DC) closed down 8.07% at 549.40 Danish Krone, marking the first time since August 7, 2023, that it closed below the psychological level of 600 (closing at 545.70 that day). SAP in Germany fell 4.78%, AstraZeneca dropped 1.91%, and LVMH and Sanofi fell by up to 0.69%. Roche, Novartis, and Nestlé rose by up to 0.87%, L'Oréal increased by 1.38%, and GlaxoSmithKline rose by 1.6%

### Related Stocks

- [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md)
- [ASML.US - ASML](https://longbridge.com/en/quote/ASML.US.md)
- [GSK.US - GSK](https://longbridge.com/en/quote/GSK.US.md)
- [AZN.US - AstraZeneca](https://longbridge.com/en/quote/AZN.US.md)
- [SAP.US - SAP AG-Sponsored](https://longbridge.com/en/quote/SAP.US.md)
- [LRLCY.US - L'Oréal S.A.](https://longbridge.com/en/quote/LRLCY.US.md)
- [NSRGY.US - Nestlé](https://longbridge.com/en/quote/NSRGY.US.md)
- [NSRGF.US - Nestlé S.A.](https://longbridge.com/en/quote/NSRGF.US.md)
- [NVS.US - NOVARTIS AG](https://longbridge.com/en/quote/NVS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 诺和诺德公司 - 股份回购计划 | 诺和诺德公司已启动一项最高达 150 亿丹麦克朗的股票回购计划，计划于 2026 年 2 月 4 日开始。截至 2026 年 2 月 13 日，公司已回购 1,750,000 股 B 类股票，平均价格为 305.03 丹麦克朗，总计为 53 | [Link](https://longbridge.com/en/news/276056741.md) |
| 诺和诺德公司提议任命两名新的董事会成员 | 丹麦制药公司诺和诺德公司提议在 3 月 26 日于哥本哈根举行的年度股东大会上新增三名董事会成员。提议的成员包括海伦娜·萨克森、扬·范·德·温克尔和拉莫娜·塞奎拉。萨克森此前已宣布辞去 Sobi 的职务以加入诺和诺德。还提议重新选举董事长拉 | [Link](https://longbridge.com/en/news/276442777.md) |
| Puzo Michael J 在诺和诺德公司 $NVO 拥有价值 32 万美元的股票持仓 | Puzo Michael J 在第三季度大幅减持了 Novo Nordisk A/S (NYSE:NVO) 的股份，减少幅度达到 86.9%，目前持有 5,775 股，价值 320,000 美元。其他机构投资者也调整了他们的持仓，True  | [Link](https://longbridge.com/en/news/276447697.md) |
| 诺和诺德公司董事会提议再次选举 Lars Rebien Sorensen 担任主席 | 诺和诺德公司董事会提议重新选举拉斯·瑞比恩·索伦森为董事长 | [Link](https://longbridge.com/en/news/276440991.md) |
| 诺和诺德公司：将在 Ozempic 和 Wegovy 专利到期时准备好替代产品 - Berlingske | 丹麦制药公司诺和诺德计划在其药物 Ozempic 和 Wegovy 的专利于 2031 年在欧洲和 2032 年在美国到期时，准备好替代药物。研究负责人马丁·霍尔斯特·朗格表示，某些临床试验中的候选药物可能会在 2030 年前提交审批。有关 | [Link](https://longbridge.com/en/news/276314777.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
